Innovative saliva test decodes biological clock and optimizes cancer therapies
TimeTeller wins Hamburg Founder Award 2025
Advertisement
They combine their groundbreaking research achievements with entrepreneurial courage: Prof. Dr. Angela Relógio, Professor of Systems Medicine at MSH, and her co-founder Dr. Benjamin Dose received the Hamburg Start-up Award 2025 in the "Start-ups" category for their start-up TimeTeller, which was founded in 2023.
TimeTeller is currently developing a saliva test to determine the internal biological clock. Its application is already being researched and tested in numerous hospitals across Germany. "If we know more about the individual circadian rhythms of patients, we can make cancer therapies, for example, more tolerable and effective in the future," says Angela Relógio, describing her project. She receives support in the form of scientific expertise and state-of-the-art laboratory infrastructure from MSH. Ilona Renken-Olthoff, founder and managing partner of MSH: "As a modern medical university, we promote innovative thinking and action. This also includes evidence-based, patient-centered care. The future of medicine will be shaped by personalization, technology and entrepreneurial thinking."
The still young company was one of the three finalists for the German Start-up Prize in the "Start-up" category, which was awarded in Berlin at the beginning of September. "The fact that we have now been awarded the Hamburger Gründerpreis 2025 by Hamburger Sparkasse and the Hamburger Abendblatt is extremely gratifying and at the same time spurs us on to bring the saliva test to market maturity," emphasizes the professor. With Techniker Krankenkasse and the venture capital company Capacura, TimeTeller has further high-caliber partners at its side. In cooperation with TK, a product that provides recommendations for daily activities to improve health is to be launched on the market by the end of 2025. Angela Relógio expects the circadian rhythm test to be fully developed and approved as a medical product in the field of oncology by 2028.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.